Page 44 - Nsclc News Today

Several studies in lung cancer have started enrolling recently – maybe one of your patients could benefit.

- The Company will discuss the topline results during its Q4 2022 results presentation on Thursday, February 16, 2023, at 10:00 AM CET - BERGEN, Norway, Feb. 15, 2023 /PRNewswire/ -- BerGenBio

A US trial showing that sublobar resection achieves similar survival outcomes as lobar resection could usher in precision lung cancer surgery, says expert.

And say— throw him into one of the cisterns and say that a ferocious animal has devoured him. may god add a blessing _ devoured him. may god add a blessing. to the reading of his word — blessing. to the reading of his word. early this morning before dawn. _ word. early this morning before dawn. i— word. early this morning before dawn, i did what i often do when i come _ dawn, i did what i often do when i come to— dawn, i did what i often do when i come to memphis. i went out to the lorra...

And all those community people who stood up forjustice even before we showed up and even before the camera showed up and even before the camera showed up and i think they deserve a big round of applause. we have the sclc president here as well. and obviously, we have the people most affected by this tragedy who are showing such grace under these tragic circumstances and that is the stepfather of tyre nichols, mr rodney wales and the mother of tyre nichols,. we could never applaud you enough for ...

SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated

The checkpoint inhibitor was associated with better survival and adverse events vs single-agent chemo for advanced NSCLC. The study was published as a preprint and has not yet been peer reviewed.

Drugmakers including Pfizer, GSK, BMS, AstraZeneca, and Sanofi plan to raise prices on more than 350 unique drugs in early January, according to data analyzed by a healthcare research firm.

The US Food and Drug Administration (FDA) has approved Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM (adagrasib). Click to read more...

NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company...